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Cyclized NDGA modifies dynamic 
α-synuclein monomers preventing 
aggregation and toxicity
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Growing evidence implicates α-synuclein aggregation as a key driver of neurodegeneration in 
Parkinson’s disease (PD) and other neurodegenerative disorders. Herein, the molecular and structural 
mechanisms of inhibiting α-synuclein aggregation by novel analogs of nordihydroguaiaretic acid 
(NDGA), a phenolic dibenzenediol lignan, were explored using an array of biochemical and biophysical 
methodologies. NDGA analogs induced modest, progressive compaction of monomeric α-synuclein, 
preventing aggregation into amyloid-like fibrils. This conformational remodeling preserved the 
dynamic adoption of α-helical conformations, which are essential for physiological membrane 
interactions. Oxidation-dependent NDGA cyclization was required for the interaction with monomeric 
α-synuclein. NDGA analog-pretreated α-synuclein did not aggregate even without NDGA-analogs 
in the aggregation mixture. Strikingly, NDGA-pretreated α-synuclein suppressed aggregation of 
naïve untreated aggregation-competent monomeric α-synuclein. Further, cyclized NDGA reduced 
α-synuclein-driven neurodegeneration in Caenorhabditis elegans. The cyclized NDGA analogs may 
serve as a platform for the development of small molecules that stabilize aggregation-resistant 
α-synuclein monomers without interfering with functional conformations yielding potential therapies 
for PD and related disorders.
Parkinson’s disease (PD) is an age-related neurodegenerative disorder characterized by a progressive motor 
phenotype including tremors, rigidity, and bradykinesia. These symptoms are driven primarily by loss of 
dopamine-producing neurons in the substantia nigra pars compacta. Lewy bodies, intracellular proteinaceous inclu-
sions, are the histopathological hallmark of PD. Immunohistochemical analysis of Lewy bodies revealed aggregated 
forms of α-synuclein, a 140 amino acid protein, as a major component1,2. Mutations, duplications, and triplications 
of the gene encoding α-synuclein cause dominantly-inherited familial forms of PD3–6. Furthermore, aggregation of 
wild type α-synuclein is involved in the pathogenesis of a diverse group of neurodegenerative diseases1,7–14.
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The pathological and genetic evidence implicating α-synuclein in neurodegeneration has sparked numerous 
studies of the normal function of α-synuclein and its role in disease pathogenesis. α-Synuclein has been impli-
cated in synaptic function15. It preferentially binds lipid membranes with high curvature16 and may modulate 
neurotransmitter release and synaptic function by affecting vesicular dynamics17–21.
Repeated studies across various animal models have shown that expression of mutant α-synuclein with altered 
aggregation kinetics causes neurodegeneration22,23. Likewise, induction of α-synuclein aggregation in wildtype 
animals by seeding with α-synuclein aggregates—isolated from PD Lewy bodies24 or generated in vitro25–28—
induces progressive neurodegeneration. Indeed, this propagation of α-synuclein aggregation is not only observed 
in animal models, but in dopaminergic tissue grafted into PD patients29. α-Synuclein aggregation also occurs in 
animal models of dopamine neuron degeneration induced by oxidative chemical insult30,31.
The implication of α-synuclein in PD pathogenesis stimulated several screens for small molecules that alter its 
aggregation. Dopamine and related catecholamines were among the first molecules found to prevent α-synuclein 
fibril formation32. Oxidation of vicinal hydroxyls in dopamine, and related phenols, induces formation of sol-
uble α-synuclein oligomers that do not incorporate into fibrils33–35. Recently, dopamine-induced α-synuclein 
oligomers were shown to contribute to neurodegeneration in mice36, but the precise mechanism of oligomer 
toxicity remains a subject of debate37. Dopamine oxidation may also contribute to neurodegeneration through 
modification of glucocerebrosidase and consequential lysosomal dysregulation38.
Ongoing research has identified many other inhibitors of α-synuclein aggregation. Many of these inhibitors 
stabilize multimers or oligomers through direct interaction with α-synuclein (e.g. various phenols, catechols, 
and flavonoids35,39–45, Anle138b46,47, rifampicin48). A well-studied member of this groups is epigallocatechin gal-
late (EGCG), a polyphenol sharing the vicinal hydroxyls implicated in dopamine’s interaction with α-synuclein. 
Despite their chemical similarities, dopamine and EGCG have divergent effects on the structure of α-synuclein49. 
In fact, while dopamine may induce toxic oligomers, adding EGCG during cell-free α-synuclein aggregation pro-
duces species less toxic to cells39. Other aggregation inhibitors alter α-synuclein-protein or -lipid interactions to 
prevent aggregation (e.g. NPT100-18A50, squalamine51, PcTS52,53, Hsp7054). Recent studies have examined small 
molecules that directly stabilize α-synuclein monomers (e.g. BIOD30355, nortriptyline56, CLR0157,58). However, 
it remains unknown whether these small molecules perturb α-synuclein’s lipid interactions, which are directly 
implicated in its role in neurotransmitter release59–61.
In this study we employed nordihydroguaiaretic acid (NDGA), a phenolic dibenzenediol lignan that inhib-
its α-synuclein aggregation, to examine the mechanisms of α-synuclein aggregation inhibitors and evaluate its 
potential utility as a chemical platform for the development of novel aggregation inhibitors40,62. Recent work 
has exhaustively characterized the products and kinetics of NDGA oxidation as well as several novel analogs 
NDGA and several novel analogs63. We provide evidence that cyclized NDGA, formed during oxidation, interacts 
with α-synuclein to produce modified monomers. We demonstrate that these aggregation-resistant monomers 
retain their capacity to interact with phospholipid membranes and that they inhibit aggregation of untreated 
α-synuclein. Further, we demonstrate for the first time that cyclized NDGA reduces α-synuclein-driven neuro-
degeneration in a relevant animal model. Generating α-synuclein species that retain native structural dynamics 
while exerting a dominant-negative effect on α-synuclein aggregation and neurotoxicity represents a new para-
digm for intervening in PD and related disorders.
Results
NDGA inhibits both primary and secondary nucleation-mediated α-synuclein aggrega-
tion. Two established assays, measurement of insoluble protein and Thioflavin-T binding, quantified the effect 
of NDGA on the aggregation of monomeric α-synuclein. NDGA caused concentration-dependent inhibition of 
insoluble α-synuclein accumulation and amyloid-like aggregate formation (Figs 1A,B and S1). Maximal inhibi-
tion was achieved at stoichiometric, equimolar concentrations of NDGA to monomeric α-synuclein. To con-
firm the Thioflavin-T findings, the secondary structure of aggregates was quantified by circular dichroism (CD). 
NDGA caused a dose-dependent decrease in the β-sheet content of the α-synuclein aggregates, as indicated by 
molar ellipticity decreases at 200 nm and increases at 220 nm (Fig. 1C). Finally, transmission electron microscopy 
was used to image the α-synuclein aggregates produced in the presence or absence of NDGA. Typical α-synuclein 
fibrils were observed in the absence of NDGA, but not after aggregation with equimolar NDGA (Fig. 1D). These 
data demonstrate that stoichiometric concentrations of NDGA inhibit the formation of amyloid-like α-synuclein 
fibrils.
The preceding experiments examined the effect of NDGA on a typical α-synuclein aggregation assay, in which 
primary nucleation is the rate-limiting step for the formation of fibrils. Aggregation of α-synuclein can also 
proceed by a secondary nucleation surface-catalyzed formation of fibrils. To test the effect of NDGA on second-
ary nucleation-dependent aggregation, α-synuclein fibrils (representing 5% of total α-synuclein) were added 
with monomeric α-synuclein. Equimolar NDGA (molecule to monomeric α-synuclein) inhibited the formation 
of insoluble α-synuclein aggregates in the presence of fibril seeds (Fig. 1E). Together, these findings demon-
strate that stoichiometric NDGA prevents both primary and secondary nucleation dependent aggregation of 
α-synuclein.
Interaction with α-synuclein requires oxidation and cyclization of NDGA. We used 
N-acetylcysteine (NAC), an electron donor, to inhibit NDGA oxidation in the presence of α-synuclein. NAC was 
included in a typical α-synuclein aggregation mixture at 20:1 molar excess to NDGA. After aggregation for 3 days, 
levels of α-synuclein aggregation were measured by the established solubility assay. mNDGA, a NDGA analog 
incapable of oxidation and cyclization was included as a negative control (Supplementary Fig. S2). The addi-
tion of NAC allowed α-synuclein to aggregate in the presence of NDGA, suggesting that oxidation is necessary 
for NDGA to inhibit aggregation (Fig. 2A,B). The inclusion of NAC also reduced levels of quinone-containing 
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NDGA oxidation products detected by near-infrared fluorescence (nIRF), a technique developed to study the 
oxidation-dependent interaction between α-synuclein and dopamine64 (Fig. 2C). The correlation of increased 
aggregation and decreased quinone nIRF suggests a relationship between NDGA oxidation and inhibition of 
α-synuclein aggregation. Separately, catalase, which rapidly converts H2O2 to water and hydrogen gas, was 
included in the aggregation assay to determine whether H2O2 that might be produced during NDGA oxida-
tion mediated the effects on aggregation. Inclusion of catalase had no effect on α-synuclein aggregation in the 
presence of NDGA nor on quinone nIRF, indicating that the effect is not H2O2-dependent (Figs 2A and S3). 
These data indicate that inhibition of α-synuclein aggregation by NDGA and formation of quinone-modified 
α-synuclein is oxidation-dependent but not mediated by peroxide chemistry.
Previous work has identified the majority product of NDGA oxidation as a cyclized form63. During that study, 
novel NDGA analogs with defined oxidation pathways were generated. Here, these analogs were used to examine 
of the role of cyclization in NDGA’s oxidation-dependent inhibition of α-synuclein aggregation. We employed 
NDGA and two such analogs: NDGA-1, which oxidizes with comparable kinetics but does not cyclize due to 
unilateral hydroxyl substitution, and NDGA-5, which cyclizes more readily than NDGA due to reduced steric 
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Figure 1. NDGA inhibits recombinant human α-synuclein aggregation. (A) Insoluble α-synuclein present 
after 7 days aggregation was reduced by NDGA and EGCG in a dose-dependent fashion as compared to solvent 
control. Recombinant human wildtype α-synuclein (138 µM) was aggregated for 7 days in the presence of 
EGCG or NDGA at the indicated molar ratios. After aggregation, PBS-insoluble α-synuclein was separated by 
centrifugation (21k g for 10 min). Soluble and insoluble fractions were boiled in SDS, run by SDS-PAGE, and 
colloidal stained. α-Synuclein in each fraction was quantified by in-gel densitometry (n = 3–5, ***p < 0.001). 
(B) Formation of amyloid α-synuclein fibrils quantified by Thioflavin-T was reduced by NDGA and EGCG  
in a dose-dependent fashion as compared to control after 7 days aggregation (n = 3–5, ***p < 0.001).  
(C) α-Synuclein beta-sheet secondary structure was reduced by EGCG and NDGA in a dose dependent 
fashion. Recombinant human wildtype α-synuclein (138 µM) was aggregated for 7 days in the presence of 
EGCG or NDGA at the indicated molar ratios. Secondary structure was quantified by circular dichroism. 
(D) Transmission electron microscopy images of α-synuclein aggregates after 3 days aggregation with small 
molecules at 1:1 molar ratio. (E) Insoluble α-synuclein present after 7 days aggregation in the presence of a 
5% fibril seed was reduced by EGCG and NDGA. EGCG or NDGA were present at a 1:1 molar ratio. After 
aggregation, PBS-insoluble α-synuclein was separated by centrifugation (21k g for 10 min). Soluble and 
insoluble fractions were boiled in SDS, run by SDS-PAGE, and colloidal stained. α-Synuclein in each fraction 
was quantified by in-gel densitometry (n = 3, ***p < 0.001).
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Figure 2. Interaction between NDGA and α-synuclein requires NDGA oxidation and cyclization. (A) NDGA 
treatment did not affect α-synuclein aggregation in the presence of N-acetylcysteine (NAC). α-Synuclein was 
aggregated for 3 days in the presence of 1:1 small molecules. After aggregation, PBS-insoluble α-synuclein 
was separated by centrifugation (21k g for 10 min). Soluble and insoluble fractions were boiled in SDS, run by 
SDS-PAGE, and colloidal stained. α-Synuclein in each fraction was quantified by in-gel densitometry. NAC was 
added at 20x molar excess to small molecule and catalase was added equal to 5% of protein, providing excess 
hydrogen peroxide decomposition capacity (n = 3–5, ***p < 0.001). (B) Colloidal staining of representative 
gels showed the formation of insoluble α-synuclein aggregates in the presence of NDGA and NAC. (C) 
Near-infrared fluorescent imaging of the same gels before colloidal staining showed a reduction of quinone-
dependent fluorescence in the presence of NAC. (D) α-Synuclein did not aggregate in the presence of cyclizable 
analogs, NDGA and NDGA-5, but did with non-cyclizable NDGA-1 (n = 3, ***p < 0.001). (E) α-synuclein 
did not aggregate in the presence of cyclized cNDGA and cNDGA-5 (n = 3). α-Synuclein was aggregated for 
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hindrance in the crosslinking region (Supplementary Fig. S2). α-Synuclein was aggregated for 3 days in the pres-
ence of equimolar NDGA analogs, and aggregation was quantified by the solubility assay. Both cyclizing analogs, 
NDGA and NDGA-5, inhibited α-synuclein aggregation, while non-cyclizing NDGA-1 did not (Fig. 2D). The 
products of the above experiment where also analyzed by nIRF. NDGA and NDGA-5-treated α-synuclein exhib-
ited quinone nIRF signals, while NDGA-1-treated α-synuclein did not (Supplementary Fig. S4). These results 
indicate that cyclized forms of NDGA, or the process of cyclization, are required for inhibition of α-synuclein 
aggregation and formation of quinone-modified α-synuclein. To address this uncertainty, α-synuclein was aggre-
gated in the presence of cNDGA and cNDGA-5, the purified cyclized forms of NDGA and NDGA-5, respectively 
(Supplementary Fig. S2). Using the solubility assay, both cNDGA and cNDGA-5 inhibited α-synuclein aggrega-
tion as potently as NDGA (Figs 2E and S5). This indicates that NDGA’s inhibition of α-synuclein aggregation is 
mediated by interaction of the protein with cyclized oxidation products.
NDGA induces modest, progressive α-synuclein compaction without preventing dynamic 
adoption of α-helical conformation. During analysis of the interaction between NDGA and α-synuclein, 
equimolar incubation consistently produced nIRF-positive quinone-modified α-synuclein (Supplementary 
Fig. S6). Based on this observation, NDGA-treated α-synuclein was further analyzed to determine any struc-
tural effects of the interaction. Native nano-electrospray ionization mass spectra (ESI-MS), collected following 
10 minute incubations of the protein-ligand mixtures, detected α-synuclein-NDGA complexes with masses 
matching the theoretical values of the unmodified protein and ligand65. This result indicates that the initial inter-
action between α-synuclein and NDGA does not require, nor produce, covalent modifications. Complexes were 
observed with higher relative intensities at low protein charge states, suggesting a preferential binding to the more 
compact α-synuclein conformations as previously observed with EGCG. However, levels of α-synuclein binding 
were much lower for NDGA than previously observed with EGCG49 (Supplementary Fig. S7).
Ion-mobility mass spectrometry (IM-MS) allows for highly sensitive detection of changes in ion compactness, 
mass, and charge. Of note, this allows subtle changes in protein conformation e.g. caused by ligand binding to 
alternative sites, to be distinguished by compactness even at the same mass and charge of the ion. Further, native 
IM-MS can resolve multiple different binding events by their conformational effects without averaging across 
the species distribution. This capability has previously been employed to show the differential effects of EGCG 
and dopamine on α-synuclein compaction49. IM-MS revealed that α-synuclein compaction was unchanged by 
incubation with either NDGA or mNDGA (Figs 3A and S7). However, incubation with cyclized NDGA analogs 
cNDGA and cNDGA-5 led to α-synuclein assuming more compact conformations (Fig. 3B). α-Synuclein did 
non-covalently bind cyclized analogs up to 3 times, as seen by the corresponding mass shifts, and further, inter-
action with greater numbers of cyclized analogs correlated with increased compaction. This finding recapitulates 
similar results after α-synuclein incubation with EGCG49 and indicates that interaction with cyclized NDGA 
causes structural compaction of α-synuclein.
NMR allowed for localization of NDGA’s structural effects within the sequence of α-synuclein. After 24 hours 
incubation with 1:1 NDGA small variations in peak positions were observed in the N-terminus – Val 3, Phe 
4, Met 5 – as well as His 50 (Fig. 3C). cNGDA and NDGA-1-treatment caused similar changes in the spec-
tra (data not shown). Incubation with 3:1 NDGA resulted in more pronounced shifts in the same set of peaks 
(Supplementary Fig. S8).
These samples were followed for several days through NMR revealing a progressive variation of the peak 
shifts. After several days, additional changes occurred in the signals of several peaks. These peaks constitute a sec-
ond set of signals, indicative of a subset of the α-synuclein population with altered conformation at these residues.
Förster resonance energy transfer (FRET) analysis of α-synuclein provided further insight into the regions 
altered by NDGA treatment. This examination employed several synthetic α-synuclein proteins with varying flu-
orescent label pairs spread throughout the amino acid sequence. Based on this methodology, FRET signal from an 
individual label pair can be converted to an intramolecular distance within α-synuclein and, when taken together, 
the multiple label pairs provided eight partially overlapped measurements covering the amino acid sequence from 
residue 9 to 13666. FRET revealed progressive changes in α-synuclein conformation when treated with EGCG, 
while NDGA, cNDGA, and mNDGA did not induce changes, even after 24 hours (Fig. 3D,E). As with IM-MS 
and NMR, NDGA-treatment was found to induce minimal changes in α-synuclein conformation, while EGCG 
showed more marked effects.
NDGA-treated and dialyzed α-synuclein examined by CD showed no changes in secondary structure further 
confirming the IM-MS and NMR analyses (Fig. 3F). Despite observing limited effects of NDGA on α-synuclein 
structure in aqueous solution, we also examined whether NDGA treatment alters the capacity of α-synuclein to 
interact with hydrophobic membranes. Membrane interaction induces the N-terminus of α-synuclein to assume 
an α-helical secondary structure67–69. Capacity for membrane interaction is necessary for α-synuclein’s putative 
biological functions in the synapse15,18,19. Neither NDGA nor mNDGA treatment prevented α-synuclein from 
assuming α-helical conformations in the presence of SDS, just as occurred under control conditions (Fig. 3G). 
This indicates that the structural changes induced by NDGA do not restrict α-synuclein dynamic flexibility.
The ability of NDGA-treated α-synuclein to interact with membranes was further examined by fluorescence 
correlation spectroscopy (FCS), which has been used extensively to study the interaction of α-synuclein with lipid 
vesicles16,70. The binding of fluorescently labelled recombinant human α-synuclein to various concentrations of 
3 days in the presence of 1:1 small molecules. After aggregation, PBS-insoluble α-synuclein was separated by 
centrifugation (21k g for 10 min). Soluble and insoluble fractions were boiled in SDS, run by SDS-PAGE, and 
colloidal stained. α-Synuclein in each fraction was quantified by in-gel densitometry.
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Figure 3. NDGA induces compaction of α-synuclein without preventing structural remodeling. (A) NDGA 
and mNDGA treatment did not alter α-synuclein collisional cross section measured by IM-MS. (B) cNDGA 
and cNDGA-5 induced α-synuclein compaction as measured by IM-MS. α-Synuclein was incubated with each 
molecule at 5:1 molar excess for 10 minutes before measurement. (C) NDGA treatment of α-synuclein did not 
induce extensive shifts in 2D NMR spectra. α-Synuclein was incubated 1:1 with NDGA for 24 hours before 
spectra were collected. NDGA-treated α-synuclein spectra (blue) was overlaid on solvent-treated α-synuclein 
(red). Fluorescein-maleimide (Fam) and tetramethylrhodamide azide (Raz) residue FRET measurement of (D) 
0 hour and (E) 24 hour small molecule treatments showed progressive alteration of α-synuclein intramolecular 
distances by EGCG, but not NDGA, cNDGA, or mNDGA. The dashed line depicts 1 µM α-synuclein treated 
with buffer (1x PBS). Treatments were 5 µM NDGA (green square), EGCG (red triangle), cNDGA (purple 
inverted triangle), and mNDGA (blue diamond) (n = 3). (F) α-Synuclein secondary structure was not altered 
by pretreatment with NDGA. (G) NDGA pretreatment did not prevent α-synuclein assuming α-helical 
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phospholipid vesicles (1:1, POPS:POPC) was compared following α-synuclein incubation for 24 hours with equi-
molar NDGA analogs or solvent alone. NDGA, cNDGA, and mNDGA did not alter phospholipid affinity as indi-
cated by similar protein binding affinity at each vesicle concentration, regardless of treatment condition (Fig. 3H). 
FCS was also used to determine whether the addition of NDGA would displace α-synuclein already bound to 
phospholipid vesicles. The fraction of α-synuclein bound to vesicles was not altered by the addition of NDGA as 
compared to the addition of solvent alone (Fig. 3I). These data further indicate that NDGA treatment does not 
perturb α-synuclein interaction with hydrophobic membranes. Similarly, EGCG did not disrupt phospholipid or 
vesicle binding (Supplementary Fig. S9). Collectively, these results show that NDGA causes α-synuclein compac-
tion across the sequence, without altering secondary structure or preventing structural remodeling involved in 
physiological function.
NGDA pretreated α-synuclein stably resists seeded aggregation. Based on the progressive remod-
eling of α-synuclein treated with NDGA, we analyzed the capacity of NDGA-pretreated α-synuclein to aggregate 
into fibrils. α-Synuclein was incubated with equimolar NDGA (as well as mNDGA and EGCG controls) for 
24 hours before dialysis against excess PBS for 24 hours. This pretreated, dialyzed α-synuclein was then aggre-
gated for 3 days before undergoing the solubility assay (as depicted in Supplementary Fig. S10). NDGA, but not 
mNDGA, pretreatment prevented α-synuclein aggregation (Fig. 4A). Further, pretreated, dialyzed α-synuclein 
was aggregated for 14 days to test the duration of the effect. Again, NDGA but not mNDGA pretreatment pre-
vented α-synuclein aggregation (Supplementary Fig. S11). Consistent with previous data, we found that pretreat-
ment with cyclizing (NDGA and NDGA-5) and cyclized (cNDGA and cNDGA-5) analogs prevented α-synuclein 
aggregation, while non-cyclizing analogs (NDGA-1 and SECO-1) did not (Supplementary Figs S12 and S13). 
We also examined the soluble species that remained following aggregation of pretreated, dialyzed α-synuclein 
using native state SEC and found that monomeric species are the majority product (Supplementary Fig. S14). 
Collectively, these findings demonstrate the NDGA pretreatment renders α-synuclein monomers resistant to 
aggregation. This effect was not observed with non-oxidizable and non-cyclizing analogs of NDGA.
Native-state size exclusion chromatographic (SEC) fractionation found that pretreatment with either NDGA 
or EGCG produces both monomeric and oligomeric α-synuclein species (Supplementary Fig. S6). We compared 
the aggregation of these two pools of α-synuclein species. α-Synuclein was incubated with equimolar concentra-
tions of small molecules for 24 hours before oligomeric (≥51 Å) and monomeric (<51 Å) species were separated 
using native state SEC. The resulting fractions were then aggregated for 3 days before analysis by the solubil-
ity assay. Both monomers and oligomers produced upon NDGA and EGCG pretreatment resisted aggregation, 
while the majority of mNDGA treatment products formed insoluble aggregates (Fig. 4b). This indicates that 
while aggregation-resistant α-synuclein oligomers do form after NDGA treatment, resulting monomers are also 
aggregation-resistant, even in the absence of oligomers.
Next, we explored whether NDGA can prevent surface-catalyzed, secondary nucleation-dependent, aggre-
gation of α-synuclein. Pretreated, dialyzed α-synuclein was aggregated for 3 days in the presence of α-synuclein 
fibril seeds (equal to 5% of total α-synuclein in solution) before aggregation was quantified by the solubility assay. 
Again, NDGA but not mNDGA pretreatment reduced α-synuclein aggregation (Fig. 4c). This demonstrates that 
NDGA-pretreated, dialyzed α-synuclein does not readily undergo secondary nucleation to form species capable 
of incorporating into existing fibrils.
Based on the observation that NDGA treatment prevents α-synuclein aggregation, we conducted a 
novel analysis to determine whether aggregation of untreated α-synuclein is altered by the presence of 
NDGA-pretreated α-synuclein. Pretreated, dialyzed α-synuclein was generated as before, then mixed with 
untreated α-synuclein at varying ratios and the resulting mixtures were aggregated for 3 days before undergoing 
the solubility assay (as depicted in Supplementary Fig. S15). The addition of pretreated, dialyzed α-synuclein 
caused a super-stoichiometric reduction in insoluble α-synuclein, demonstrating that aggregation of untreated 
α-synuclein was reduced (Fig. 4d). This effect is demonstrated in the 20% condition wherein NDGA pretreated, 
dialyzed α-synuclein represents only 20% of total α-synuclein, but insoluble α-synuclein is reduced from 88% 
in control conditions to 37%. These data, taken in totality, indicate that pretreatment with NDGA produces 
α-synuclein monomers that are not only resistant to aggregation, but reduce aggregation of α-synuclein never 
exposed to NDGA.
cNDGA reduces α-synuclein-driven dopamine neurodegeneration in animals. We examined the 
effect of NDGA and cNDGA treatment on α-synuclein-driven neurodegeneration (Fig. 5A,B). We employed a 
widely used, Caenorhabditis elegans (C. elegans) model in which expression of human wildtype α-synuclein in 
dopaminergic neurons leads to progressive neurodegeneration71. Animals were treated with varying doses of 
NDGA, or cNDGA from hatching until the day before scoring on either day 6 or day 8. Animals were consid-
ered to be undergoing neurodegeneration if any dopamine neurons were absent or dendritic processes showed 
signs of dysfunction such as blebbing72. Representative images of animals scored during this experiment show 
secondary structure in the presence of SDS micelles. α-Synuclein was incubated 1:1 with NDGA, mNDGA, 
or solvent alone for 24 hours and then dialyzed against PBS for 24 hours. 40 mM SDS micelles were added 
5 minutes before analysis. Secondary structure was quantified by circular dichroism. (H) NDGA treatment did 
not alter α-synuclein phospholipid binding. α-Synuclein was incubated 1:1 with NDGA analogs or solvent 
alone for 24 hours before fluorescence correlation spectroscopy in the presence of POPS:POPC vesicles at the 
indicated concentrations (n = 3). (I) Addition of NDGA did not displace fluorescently labeled α-synuclein from 
POPS:POPC vesicles (n = 3).
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the loss of fluorescent dopamine neuron processes and bodies in solvent and NDGA-treated animals (Fig. 5B). 
No differences were observed in NDGA or cNDGA treated animal after day 6 (data not shown). cNDGA at all 
concentrations (10, 50 and 100 µM) significantly reduced the number of animals undergoing dopamine neu-
ron degeneration at day 8 (Fig. 5A). Similarly, EGCG (50 µM) protected against neuron loss (Supplementary 
Fig. S16). In this model, expression of α-synuclein was limited to just six neurons with each animal. As such, total 
α-synuclein levels were so low as to preclude biochemical analysis of the interaction between α-synuclein and 
NDGA or cNDGA. Likewise, we were unable to conduct pharmacokinetic analysis of our target neurons. Despite 
these limited reservations, these results demonstrate, for the first time, that cNDGA can reduce neurodegenera-
tion caused by α-synuclein.
Discussion
Because of the engagement in several neurodegenerative diseases, α-synuclein aggregation remains a promising 
target for therapeutic development. Using NDGA and novel analogs, we uncovered that NDGA oxidation and 
cyclization was required for formation of quinone-modified monomeric α-synuclein. This interaction caused 
slight compaction of the α-synuclein molecule but did not induce any noticeable changes in its intrinsically 
Figure 4. NDGA pretreatment prevents α-synuclein aggregation. (a) α-Synuclein did not aggregate 
after pretreatment with NDGA. α-Synuclein was incubated 1:1 with small molecules for 24 hours then 
dialyzed against PBS for 24 hours. After aggregation for 3 days, PBS-insoluble α-synuclein was separated by 
centrifugation (21k g for 10 min). Soluble and insoluble fractions were boiled in SDS, run by SDS-PAGE, and 
colloidal stained. α-Synuclein in each fraction was quantified by in-gel densitometry (n = 3, ***p < 0.001). 
(b) Both oligomeric and monomeric α-synuclein species induced by NDGA treatment resist aggregation. 
α-Synuclein was incubated 1:1 with small molecules for 24 hours then subjected to native state size exclusion 
chromatography. Oligomeric (≥51 Å) and Monomeric (<51 Å) α-synuclein fractions were collected and 
aggregated separately for 3 days. Soluble and insoluble species were separated and quantified as above (n = 3). 
(c) NDGA-treated α-synuclein resisted fibrillization in the presence of 5% fibril seed. α-Synuclein was 
incubated 1:1 with small molecules for 24 hours then dialyzed against excess PBS for 24 hours. Untreated 
α-synuclein fibrils equal to 5% total protein was added immediately before mixtures were aggregated for 
3 days. Soluble and insoluble species were separated and quantified as above (n = 3, ***p < 0.001). (d) 
NDGA pretreated, dialyzed α-synuclein inhibited aggregation of untreated α-synuclein. α-Synuclein was 
incubated 1:1 with small molecules for 24 hours then dialyzed against excess PBS for 24 hours. Pretreated, 
dialyzed α-synuclein was then mixed with untreated monomeric α-synuclein at the indicated ratios. Mixtures 
were aggregated for 3 days. Soluble and insoluble species were separated and quantified as above (n = 3, 
***p < 0.001).
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disordered state. Furthermore, NDGA-treated α-synuclein retained its ability to undergo conformational changes 
required for interaction with the membranes, and NDGA did not dissociate protein-membrane complexes. 
However, interaction of α-synuclein with NDGA and its cyclizing and cyclized analogues efficiently prevented 
α-synuclein aggregation into fibrils. Conversely, non-cyclizing NDGA analogs had no effect on fibril formation, 
ensuring the aggregation resistant effects of NDGA and its analogs is not an artifact of reduced contact between 
α-synuclein molecules. Indeed, NDGA-treated monomers not only resisted aggregation, but prevented aggrega-
tion of naïve untreated α-synuclein. Treatment with cNDGA reduced neurodegeneration in an animal model of 
α-synuclein neurotoxicity. Taken together, these findings suggest that NDGA and related molecules that prevent 
α-synuclein aggregation without perturbing its native intrinsic disorder, or associations, may be promising tar-
gets for PD and related disorders characterized by α-synuclein aggregation.
Attempts to develop therapeutic strategies targeting α-synuclein have included decreasing levels by altering 
expression73 and clearance74,75, immunological targeting76,77, and altering aggregation. Many aggregation inhib-
itors were identified through chemical library screens before being subjected to mechanistic analysis32,40,41. The 
neurotransmitter dopamine, and molecules that share structural and chemical similarities, were the first inhibi-
tors identified and are among the most potent inhibitors of α-synuclein aggregation32.
Identification of dopamine and related phenols as inhibitors of α-synuclein aggregation has led to many stud-
ies of phenolic compounds as potentially neuroprotective inhibitors. The most studied of these is EGCG, which 
is currently undergoing clinical trials in multiple system atrophy, a synucleinopathy characterized by microglial 
inclusions78. EGCG was found to be neuroprotective in animals treated with MPTP (1-methyl-4-phenyl-1,2,3,6
-tetrahydropyridine), which is a prodrug to the neurotoxin MPP+ (1-methyl-4-phenylpyridinium) that induces 
α-synuclein-dependent dopaminergic neurodegeneration79–81. Adding EGCG during in vitro α-synuclein aggre-
gation results in generation of less toxic aggregated products39. Given the structural differences between EGCG 
and NDGA, as well as the existing knowledge about NDGA oxidation and the availability of analogs, we hope 
Figure 5. cNDGA reduces α-synuclein-driven neurodegeneration (A) cNDGA, but not NDGA reduces 
dopaminergic neurodegeneration in C. elegans expressing wildtype α-synuclein. Animals were exposed to each 
concentration of the drugs on days 0–3, 5, and 7 post-hatching. Animals were scored on day 8 post-hatching 
for dopaminergic neurodegeneration. The data are represented as mean ± SEM; one-way ANOVA with Tukey’s 
post hoc test for multiple comparisons (n = 3; 30 animals per replicate; *p < 0.05; ns, not significant). (B) 
Representative images from day 8 post-hatching. Arrowheads indicate intact neurons while arrows indicate 
degenerating or missing neurons. Scale bar represents 10 µm.
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that studying NDGA as an α-synuclein aggregation inhibitor will provide new insight into the neuroprotective 
potential of inhibiting α-synuclein aggregation.
Our analysis revealed some substantial departures between the effects of NDGA and EGCG on α-synuclein. 
Konijnenberg et al. found, using IM-MS, that EGCG induces α-synuclein compaction49, while analysis conducted 
by the same group for this study showed that cNDGA and cNDGA-5 induce α-synuclein compaction (Fig. 3A,B). 
NDGA, however, did not induce α-synuclein structural change. Interestingly, FRET found that EGCG causes 
substantial α-synuclein remodeling, while NDGA and cNDGA have no measurable effect on intramolecular 
distances (Fig. 3C). We also observed consistent differences in the patterns of SDS-stable multimers present after 
α-synuclein was treated with EGCG and NDGA (Figs 2B and S3, S6, S14). This trend of subtle, but measurable, 
differences between the effect of the two molecules leaves open the possibility of different mechanisms of their 
interaction with α-synuclein and differing biophysical properties of the resulting species.
Previous studies of EGCG have focused on the oligomers formed when α-synuclein is aggregated in the pres-
ence of EGCG39,82,83. In this study, we found that α-synuclein aggregation in the presence of EGCG and NDGA 
does produce oligomers, but that monomers are the predominant product, representing more than 75% of sol-
uble protein (Supplementary Fig. S14). Further, we found that α-synuclein monomers and oligomers induced 
by pretreatment with EGCG and NDGA both resisted aggregation (Fig. 4b). The corresponding aggregation 
experiments were conducted after applying size-exclusion chromatography, which removed from solution any 
EGCG or NDGA not interacting with α-synuclein, suggesting a stable interaction or modification of α-synuclein 
itself. Most strikingly, NDGA-pretreated species inhibited aggregation of untreated α-synuclein, suggesting a 
dominant-negative effect on aggregation. This effect, not previously described for EGCG or any other exogenous 
phenolic inhibitors, may contribute to their neuroprotective effects.
There are two proposed models of amyloid-like fibril formation and elongation, although the precise mech-
anism remains unclear. In the first model monomers form oligomers and oligomers then stack together to form 
fibrils. In the second model of fibril formation, oligomers are elongated to fibrils with the addition of monomers. 
Under either paradigm, the data indicate that NDGA or EGCG modified oligomers do not progress to insol-
uble species. Possibly due to the increased compaction, monomeric α-synuclein treated with NDGA analogs, 
when incorporated into oligomers or fibrils may prevent further elongation. Essentially, the addition of a NDGA 
analog-modified α-synuclein monomer will “cap” the aggregation intermediate preventing the further addition 
of either monomer or oligomer. The stoichiometry would indicate that under either model the incorporation of 
aggregation resistant NDGA or EGCG modified monomer into oligomers or fibrils is sufficient to prevent further 
aggregation. The combination of a durable modification of α-synuclein and a dominant negative effect on aggre-
gation are very desirable, given concerns over polyphenol bioavailability in the brain84 and the hepatotoxic side 
effects seen with EGCG or NDGA78,85.
Lipid-bound α-synuclein is resistant to aggregation86, and appropriate membrane interactions are implicated 
in its physiological function87. As such, an ideal therapeutic targeting α-synuclein aggregation would allow nor-
mal lipid interaction. Interestingly, both CD and FCS showed that the membrane interactions of α-synuclein were 
not perturbed by NDGA-treatment (Fig. 3G–I). Preservation of α-synuclein membrane interaction may help 
explain the divergent effects of NDGA and dopamine on neuron viability. Indeed, α-synuclein oligomers induce 
membrane destabilization and dopamine-induced oligomers may contribute to neurodegeneration in synuclein-
opathies36,37. Further, the ability of α-synuclein to undergo native structural dynamics is necessary for formation 
of multimers implicated in physiological function59,60 and aggregation resistance88,89. Future studies aimed at 
identifying neuroprotective α-synuclein aggregation inhibitors would be well served by incorporating methods 
to determine whether membrane interactions and structural dynamics are maintained, as is the case with NDGA.
NDGA pretreatment induced an NMR peak shift at His 50 (Fig. 3C). His 50 is located within the second 
region that assumes an α-helix during α-synuclein interaction with curved lipid membranes, falling in sequence 
just after the fourth lysine-rich repeat67,69. His 50 also mediates an oligomer-stabilizing interaction between 
α-synuclein and divalent metal ions, particularly Cu(II)90,91. Additionally, His 50 to Gln mutation causes auto-
somal dominant familial PD and accelerates α-synuclein aggregation in vitro92–94. This suggests that interaction 
with His 50 could alter α-synuclein aggregation kinetics. Further investigation of the interaction between NDGA 
and His 50 might provide insight into NDGA’s inhibition of α-synuclein aggregation. Curiously, three other 
residues whose positions were perturbed by NDGA binding (Val 3, Phe 4, and Met 5) are located in the close 
proximity to the Asp 2, which is also engaged in Cu(II) binding95.
The chemistry underpinning dopamine and related small molecule modulators of α-synuclein aggregation 
includes the capacity for auto-oxidation and the presence of vicinal hydroxyl (catechol) moieties33,35. In this study, 
we have expanded the previous observations and documented many new mechanistic insights for the biochem-
istry of catechol structures to inhibit the aggregation of α-synuclein. We found that NDGA-analogs require two 
pairs of vicinal hydroxyls to interact with α-synuclein. NDGA-1, which contains only one pair of vicinal hydroxyl 
groups, did not modify α-synuclein or inhibit aggregation. This indicates that NDGA cyclization, which is ena-
bled by its two pairs of vicinal hydroxyls, is required for inhibition of α-synuclein aggregation63. Indeed, cNDGA 
and cNDGA-5, two cyclized analogs of NDGA, were found to inhibit α-synuclein aggregation. The finding that 
NDGA’s cyclized oxidation products are responsible for its effects on α-synuclein aggregation presents the dual 
opportunities to study NDGA as a prodrug, with potential for conversion by oxidation-dependent cyclization to 
active cNDGA, and to examine novel molecules based on the cNDGA structure in hopes of identifying inhibitors 
of α-synuclein aggregation.
The importance of NDGA cyclization is reinforced by the finding that cNDGA, but not NDGA, treatment 
reduces neurodegeneration caused by expression of human α-synuclein in dopamine neurons in C. elegans 
(Fig. 5). There are many potential explanations for the divergent effects of the two molecules, including differ-
ences in stability, uptake, metabolism, and excretion. One possibility is that NDGA does not form cNDGA under 
these conditions. Oxidation of NDGA likely occurs less frequently in the reducing environment of the cell96, 
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and yield of cNDGA may be lower than previously observed. While the cyclization of NDGA has been precisely 
described under controlled conditions in buffer63, it has never been examined in a complex milieu or within a 
living cell, where other chemistry may occur.
It could be of interest to compare the molecular mechanism of action of NDGA on α-synuclein with the 
effects of different small molecules on functionality of other intrinsically disordered proteins. One of the best 
studied examples of such systems is given by small molecule-driven inhibition of heterodimerization of the tran-
scription factor c-Myc with its partner, Max, via a basic-helix-loop-helix-leucine zipper (bHLHZip) domain 
present in both proteins. Importantly, both proteins in their unbound forms are disordered, but undergo mutual 
coupled binding and folding when their zipper domains interact to form a helical coiled coil97–99. High through-
put screening uncovered several specific inhibitors that were able to bind to one of three discrete sites (resi-
dues 366–375, 375–385, and 402–409) within the 85-residue bHLHZip domain of the monomeric c-Myc100,101. 
Solution NMR analysis revealed that interaction of said small molecules with c-Myc resulted in its local misfold-
ing, thereby generating conformations incompatible with the heterodimerization of this protein with Max97–99. 
Clearly, the mechanism of NDGA action, where a small molecule stabilizes specific conformations of intrinsically 
disordered α-synuclein, is principally different from the inhibitory activity of small molecules inducing c-Myc 
misfolding. Therefore, further study is warranted to determine whether the interaction between NDGA and 
α-synuclein represents a new mode of modulatory action of small molecules on intrinsically disordered proteins. 
Moreover, in-cell NMR data indicated that molecular crowding agents present in the cytosol induce compaction 
of α-synuclein and shielding of the aggregation prone region (hydrophobic core between residues 61–95) pre-
venting oligomerization and aggregation102. Although ensemble-based techniques (FRET or NMR) are not able 
to visualize and inform on the structures of these compact states, we speculate that the compact states observed 
by NDGA analogs and EGCG are similar to those observed with in-cell NMR.
Collectively, these findings change our understanding of the mechanisms of phenolic α-synuclein aggrega-
tion inhibitors. We demonstrate, for the first time, that inhibition of α-synuclein aggregation by NDGA requires 
oxidation-dependent cyclization, reframing NDGA as a prodrug. Additionally, we show that both NDGA and 
EGCG stably modify α-synuclein monomers, rendering them aggregation incompetent. In the case of NDGA, 
this is achieved without alteration of α-synuclein secondary structure in solution, nor perturbing membrane 
interactions. This combination of attributes has not been previously observed in other inhibitors of α-synuclein 
aggregation. Further examination is certainly warranted, including a full characterization of efficacy and critically 
toxicity, to determine whether NDGA analogs might provide the basis for novel neuroprotective therapies for PD 
and related synucleinopathies.
Methods
In vitro α-synuclein aggregation analyses. Recombinant human wild type α-synuclein was expressed 
and purified from E. coli as previously described103. Purified α-synuclein was used at 2 mg/ml (138 µM) with or 
without small molecules at various molar ratios in PBS with 1% DMSO. Mixtures were aggregated for 3 or 7 days 
at 37 °C shaking at 1400 rpm. The longer 7 day incubation was performed to ensure the treatment effects remained 
consistent even under prolonged aggregation. Alternatively, purified α-synuclein was incubated for 24 hours with 
or with equimolar small molecules in PBS with 1% DMSO. Resulting mixtures were then dialyzed against excess 
PBS for 24 hours at 4 °C (using mini-dialysis tubes, Thermo Fisher 69572). Mixtures were aggregated for 3 or 
14 days shaking at 1400 rpm. Amyloid fibril formation was monitored by thioflavin T. Briefly, 4 µM protein was 
incubated with 25 µM ThT (Sigma Aldrich) dissolved in PBS and read at Ex of 450 and Em 482 using a fluorescent 
plate reader (Molecular Devices).
α-Synuclein solubility analysis and densitometric quantification. Sedimentation was performed by 
centrifugation at 21,000 g for 15 minutes. Supernatants were removed, and pellets were resuspended in an equal 
volume. Pellets and supernatants were boiled in SDS sample buffer for 3 minutes at 95 °C. α-Synuclein species 
were resolved by SDS-PAGE in 12% Bis/Tris gels and stained in-gel with colloidal blue (Invitrogen LC6025). 
Stained gels were imaged at 700 nm using LI-COR Odyssey Infrared Imaging System and densitometric quantifi-
cation was conducted using LI-COR Odyssey software suite 3.0.
Near infrared fluorescence. SDS-PAGE gels were imaged as previously described64. Briefly, gels were 
imaged immediately after electrophoresis at 700 nm with intensity 10 on LI-COR Odyssey Infrared Imaging 
System.
Size-exclusion chromatography. For size exclusion chromatography 200 µL recombinant α-synuclein 
(2 mg/mL) was injected onto a Superdex 200 10/300 GL (GE Healthcare) connected to an Agilent 1100 series 
HPLC system and fraction collector controlled by ChemStation software version 1.04 (Agilent). Mobile phase 
consisted of 25 mM HEPES and 150 mM NaCl, pH 7.25 with a 0.3 mL/min flow rate. Fractions corresponding to 
140-100, 100-85, 85-75, 75-68, 68-61.5, 61.5-56, 56-51, 51-47, 47-43, 43-39, 39, 39-36, 36-32, 32-29, 29-26 Å were 
combined and concentrated using 3 kDa NMWL ultracel microcon filters (Millipore UFC5003). SEC column 
elution time was calibrated to Å size using globular protein standards (GE Healthcare).
Circular dichroism. Circular dichroism spectra were obtained on a Jasco-810 spectropolarimeter maintained 
in the Children’s Hospital of Philadelphia Protein Core facility. Protein in PBS was diluted to 20 μM in 0.05 M 
KH2PO4 pH 7.8. Spectra were corrected for baseline measurement of an equivalent volume of PBS diluted in 
KH2PO4 buffer. Spectra were collected with a scanning width of 1 nm, at 5 nm/min with 2 accumulations per run.
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Transmission electron microscopy. Transmission electron microscopy was conducted on a JEOL1010 
maintained in the University of Pennsylvania Electron Microscopy Resource Laboratory. Protein solutions were 
diluted to 0.5 mg/mL (34.5 µM) before mounting to carbon-coated 300 grids and negative staining with 2% 
uranium acetate. Images were collected with HV = 80.0 kV, Magnification 50,000x. Contrast was automatically 
adjusted during capture for each image, and not altered after capture. 1 µm scale bars were included for each 
image presented.
Nuclear magnetic resonance spectroscopy. To provide atomic resolution information on α-synuclein, 
2D 1H-15N NMR spectra were acquired through a series of band-selective excitation short-transient transverse 
relaxation optimized spectroscopy heteronuclear single quantum coherence (BEST-TROSY HSQC) runs104, a 
fast and common experiment used to evaluate if there is an effect of the different molecules on some amino acids, 
each of them represented by a HN-N correlation (a cross-peak in the 2D spectrum).
All the NMR experiments were recorded on a Bruker Avance III spectrometer operating at 900 MHz 1H fre-
quency (21.14 T) equipped with a cryogenically cooled probehead for triple resonance experiments (TCI). The 
pulses involved in this pulse sequence were the standard ones used to investigate bio-molecules105. The 15N hard 
pulses were applied at the center of the region (117.02 ppm) and the 1H band selective pulses were applied at the 
center of the amide proton region at 8.70 ppm. A spectral width of 10822.511 Hz in the direct 1H dimension and 
3647.991 Hz in the indirect 15N dimension was used. All the spectra were recorded with 8 scans per increment, 
4096 and 2048 points in the direct dimension and in the indirect dimension respectively and a recycle delay of 
500 ms.
The experiments were recorded at 288.0 K on a 165 μM uniformly 15N labeled α-synuclein sample, prepared 
as previously described106, in buffer (10 mM KPi, 140 mM NaCl, 0.25 mM EDTA + Roche protease inhibitors, pH 
7.5). 5% D2O was added for the lock signal. The different drugs (described above) were added as DMSO solutions 
at 1:1 stoichiometric ratio and left at room temperature 24 hours to incubate before NMR measurements. The 
same experiments were acquired on a sample containing 3 equivalents of NDGA. Care was taken to minimize the 
volume of the DMSO solution added and to keep it constant for all the samples investigated. All the samples were 
analyzed again in the following days to evaluate thermodynamic and kinetic effects.
Native nano-electrospray ionization mass spectrometry. ESI-MS experiments were conducted as 
previously described49. The only methodological departure was the inclusion of DMSO to solubilize the ligands. 
Briefly, MS spectra were collected after 10 minute incubation of protein-ligand mixtures in pH 7.4 10 mM ammo-
nium acetate. Spectra were collected using a hybrid quadrupole-time-of-flight mass spectrometer (QSTAR-Elite, 
Biosystems, Foster City, CA) equipped with a nano-ESI sample source.
Native Ion mobility mass spectrometry. Native Ion mobility-mass spectrometry (IM-MS) experiments 
were conducted as previously described49. The only methodological departure was the inclusion of DMSO to 
solubilize the ligands. Briefly, MS spectra were collected after 10 minute incubation of protein-ligand mixtures in 
pH 7.4 10 mM ammonium acetate. α-Synuclein was present in the mixtures at 20 µM, ligand at 100 µM. IM-MS 
was performed on a Synapt G2 HDMS (Waters, Manchester, U.K.) using nano-ESI with homemade gold-coated 
borosilicate capillaries.
Fluorescence correlation spectroscopy. Expression of fluorescently-labeled α-synuclein. α-Synuclein 
protein labeled at residue S9C with Alexa Fluor 488 was produced via recombinant protein production. Plasmid 
containing α-synuclein S9C fused to a polyhistidine-tagged GyrA intein from Mycobacterium xenopi (Mxe) 
was transformed into BL21 DE3 competent cells by heat shocking at 42 °C. Single colonies grown on Ampicillin 
(Amp) plates were picked to inoculate primary cultures in LB supplemented with 1 μg/mL Amp. Primary cultures 
were combined into secondary cultures, which were grown at 37 °C in a shaker-incubator until optical density 
(OD) reached ~0.6. Expression of the gene of interest was induced with Isopropyl β-D-1-thiogalactopyranoside 
(IPTG). Cells were then grown in the shaker-incubator at 18 °C overnight. After centrifugation (5000 rpm, 
20 min, 4 °C), cell pellets were re-suspended in re-suspension buffer (20 mM Tris, 1 mM PMSF, 1 Roche protease 
inhibitor tablet, pH 8.3) and sonicated in a cup in an ice bath (5 min, 1 s ON, 1 s OFF). The resulting lysate was 
centrifuged (14,000 rpm, 25 min, 4 °C), and supernatant containing the protein of interest (POI) was purified 
over Ni-NTA affinity column. Intein cleavage was carried out by incubation with 200 mM β-mercaptoethanol 
(βME) on a rotisserie over night at room temperature. Cleaved POI was dialyzed into 20 mM Tris pH 8 before 
purification over a second Ni-NTA column to remove the free intein from the sample. Flow-through containing 
the POI was kept, dialyzed into 20 mM Tris pH 8, and spin concentrated. Labeling with Alexa Fluor 488 (AF488) 
maleimide was done by adding 4 equivalents (eq.) of fluorophore dissolved in DMSO. The reaction tube was 
wrapped in aluminum foil and incubated at 37 °C for ~6 hrs. Formation of the product α-synuclein C9-AF488 
was checked by matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) and polyacrylamide 
gel electrophoresis (SDS-PAGE). Labeled protein was purified by fast-protein liquid chromatography (FPLC) 
using a Hi-Trap Q 5 mL column and by reverse-phase high-performance liquid chromatography (RP-HPLC) 
using a C18 preparatory column. Purified protein was spin concentrated into buffer (20 mM Tris, 100 mM NaCl), 
and aliquots were stored at −80 °C.
Treating α-synuclein with drug molecules. The concentration of α-synuclein aliquots was determined by UV-Vis 
at 488 nm. The drug molecules NDGA, mNDGA, and cNDGA were dissolved in DMSO and diluted 10-fold into 
buffer (20 mM Tris, 100 mM NaCl). A control of 10% DMSO in buffer was also made. Each aliquot of α-synuclein 
was respectively treated with 1eq. of NDGA, mNDGA, and cNDGA, and DMSO-buffer. Treatment samples were 
incubated at room temperature for 8 hours, then dialyzed against 10 mM Tris, 100 mM NaCl overnight.
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Preparation of lipid vesicles. Synthetic lipid vesicles were prepared for use in binding experiments. A mix-
ture in 50:50 molar ratio of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine (POPS) and 1-palmitoyl-2
-oleoyl-sn-glycero-3-phosphocholine (POPC) were drawn from chloroform stock and dried under nitrogen gas 
to form a film inside a glass vial. Films were desiccated under vacuum and re-hydrated in 3-(N-morpholino)
propanesulfonic acid (MOPS) buffer. 10 Freeze-thaw cycles consisting of cooling in liquid nitrogen for 40 s and 
warming in a 60 °C water bath for 2 min were performed to aid the formation of uniformly sized vesicles. Using 
syringes fitted onto an extruder, vesicles were pushed 31 times through 50 nm pore membranes. Vesicles were 
determined by Dynamic Light Scattering to be monodisperse and distributed uniformly around 80 nm in diame-
ter, consistent across different concentrations of all samples. All lipid vesicles were prepared fresh and used within 
48 hours of extrusion.
Fluorescence correlation spectroscopy. Eight-well chambered coverglasses (Nunc, Rochester, NY) were prepared 
by plasma cleaning followed by incubation over night with polylysine-conjugated polyethylene glycol (PEG-PLL), 
prepared using a modified Pierce PEGylation protocol (Pierce, Rockford, IL). PEG-PLL coated Chambers were 
rinsed with and stored in Milli-Q water until use. FCS measurements were done on a lab-built instrument based 
on an Olympus IX71 microscope with a continuous emission 488 nm DPSS 50 mW laser (Spectra-Physics, Santa 
Clara, CA). All measurements were done at 20 °C. The laser power entering the microscope was adjusted to 4.5 
μW. Fluorescence emission collected through the objective was separated from the excitation signal through a 
Z488rdc long pass dichroic and an HQ600/200 m bandpass filter (Chroma, Bellows Falls, VT). Emission signal 
was focused through a 50 μm optical fiber. Signal was amplified by an avalanche photodiode (Perkin Elmer, 
Waltham, MA) coupled to the fiber. A digital autocorrelator (Flex03Q-12, correlator.com, Bridgewater, NJ) was 
used to collect 30 autocorrelation curves of 30 seconds for each measurement. Fitting was done using MATLAB 
(The MathWorks, Natick, MA).
Binding assay of drug-treated α-synuclein to lipid vesicles. FCS was used to examine the binding affinity of 
drug-treated α-synuclein to lipid vesicles. Each drug-treated α-synuclein labeled with AF488 was examined in 
the presence of varying concentrations of lipid vesicles, and each autocorrelation curve was fit to a 2-component 
equation to extract the fraction of bound α-syn at each concentration. From these data, a binding curve was 
generated and fit to an exponential to determine the dissociation constant Kd, i.e. the concentration at which 
half of the protein is bound. In fitting the autocorrelation curves for α-syn in the presence of lipid vesicles, the 
diffusion time (τ) of bound and unbound α-syn were respectively fixed to experimentally determined values. The 
diffusion time of unbound protein, ταS, was determined by measurements of the protein in buffer without lipids. 
Since bound protein diffuses with the vesicles to which they are bound, the diffusion time of the vesicles, τvesicle, 
was determined by measurements of BODIPY-labeled 50:50 POPS/POPC. The diffusion time of our unlabeled 
vesicles were also deduced from a calibration curve generated from the diffusion times of commercial fluorescent 
bead standards of 50 nm and 100 nm in diameter.
To generate a vesicle-binding curve, FCS was performed on α-syn C9-AF488 in the presence of varying con-
centrations (0.005 mM to 1 mM lipid) of 50:50 POPS/POPC. The accessible surface lipid concentration was cal-
culated based on the characteristic bilayer thickness of POPS and POPC. The fraction of bound protein was 
extracted from the fit to each autocorrelation curve by fixing ταS and globally fitting τvesicle to the same value 
across all concentrations.
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The fraction bound was plotted against accessible lipid concentration and fit to an exponential, from which 
the Kd was determined.
=
+
F B x
K xB
max
d app,
Assay for effect of NDGA on lipid-bound α-synuclein. Untreated α-synuclein C9-AF488 (final concentration 
20 μM) was added to 250 μL of 0.05 mM POPS/PC in a microscope chamber well. The sample was incubated for 
15 minutes to ensure maximum binding interactions. NDGA stock was made by dissolving the drug in ethanol 
and diluting 10-fold into buffer (20 mM Tris, 100 mM NaCl). NDGA was added at 20 μM final concentration to 
the vesicle-bound α-synuclein sample, and fraction of protein bound was determined using the fitting described 
above. A control treatment was made of 10% ethanol in buffer, and fraction of protein bound was determined in 
the same manner.
Förster resonance energy transfer anaylsis. Small molecule stock solutions containing either NDGA, 
EGCG, cNDGA or mNDGA were prepared in DMSO. Labeled proteins constructs, including new constructs 
not previously described, were prepared using methods previously described66. Labeled positions not previ-
ously reported were confirmed by mass spectrometry of both the full-length protein and fragments from trypsin 
digestion using MALDI. The concentration of each protein stock was assessed by UV-Vis absorbance of the 
attached fluorescein-maleimide (Fam) (ε494 = 68,000 M−1 cm−1) and/or tetramethylrhodamide azide (Raz) 
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(ε555 = 87,000 M−1 cm−1) dyes. Fluorescence assays were performed in a black, clear bottom half-diameter Greiner 
96-well plate and measurements were taken on a Tecan M1000 plate reader. Each well of the plate contained a 
single protein sample, containing either one or both fluorescent labels, and one of the small molecules of interest. 
Protein samples were also measured in the absence of small molecules as a control. Each sample was prepared in 
1X PBS with a final concentration of 1 μM protein. Samples containing NDGA, EGCG, cNDGA and mNDGA 
were prepared with a 5-fold excess of small molecules relative to the protein concentration. Small molecule stocks 
were prepared just prior to performing the assay. Each assay was performed by diluting the protein in buffer in 
each well and adding the small molecule solution, using a multichannel pipette, just prior to measuring the flu-
orescence. Each sample was excited at 494 nm and the emission spectrum was measured from 502–700 nm with 
a 1 nm step size. Each step consisted of 50 flashes at a frequency of 400 Hz with a 20 μs integration time and the 
gain was set to 135. The Z-position of the plate was optimized prior to the first measurement and was maintained 
at 21728 μm for all measurements. All measurements were performed at room temperature. After measuring the 
emission spectrum from each well immediately after the introduction of small molecule, the plates were sealed 
with parafilm and covered in aluminum foil and left at room temperature for 24 hrs. After 24 hrs the fluorescence 
of each sample was measured again as detailed above. The FRET between Fam and Raz probes attached to a single 
protein was assessed by computing the fluorescence quenching of the donor Fam fluorophore induced by the 
presence of the Raz acceptor as previously described66. FRET efficiencies were converted to average interresidue 
distances using the Förster equation and a gaussian chain polymer model.
Analysis of dopaminergic neurodegeneration in C. elegans. Generation of transgenic nema-
todes. Transgenic C. elegans lines were generated by microinjection using previously described methods107. The 
strain UA294 (baEx175 a,b,c [Pdat-1::WT a-syn, Punc-54::tdTomato]; vtIs7[Pdat-1::GFP]) was generated by injecting 
with a solution of 50 ng/μL plasmid with either Pdat-1::WT a-syn with a phenotypic marker (Punc-54::tdTomato, 
50 ng/μL, for body wall muscle expression). Three distinct stable lines (a, b, c) were generated.
Analysis of dopaminergic neurodegeneration and NDGA analog treatments in C. elegans. NDGA and cNDGA 
were used at final concentrations of 10 µM, 50 µM, or 100 µM in ethyl acetate (EtAc). NDGA, cNDGA, or solvent 
(EtAc) was added to the surface of bacterial lawn on the nematode growth medium (NGM) Petri plates (60 mm 
diameter) at the corresponding final concentration and allowed to dry under the hood. For EGCG, 50 µM was 
added into the NGM agar plates. Three resulting independent transgenic lines (a, b, c) were synchronized, and 
exposed to corresponding concentration of NDGA, cNDGA, or solvent (EtAc) from hatching to day 3, then 
were transferred and maintained on NGM plates until the day of analysis. Animals on NGM plates were treated 
with additional NDGA, cNDGA, or solvent on days 5 and 7. For EGCG treatment, worms were transferred to 
fresh NGM plates daily and transferred onto fresh EGCG containing plates on days 0–3 and 5 post-hatching. 
For dopaminergic neurodegeneration analyses, the transgenic animals were scored as described previously72. 
Briefly, on the day of analysis, the six anterior dopaminergic neurons (four CEP (cephalic) and two ADE (anterior 
deirid)) were examined in 30 randomly selected nematodes with the marker transgene (tdTomato) in the body 
wall muscle cells. Worms were considered normal when all six anterior neurons were present without any signs of 
degeneration, such as broken dendritic process, cell body loss, dendritic blebbing, or a missing neuron. In total, 
at least 90 adult worms were analyzed for each treatment condition, at least 30 from each independent transgenic 
line. An average of total percentage of worms with normal neurons was reported in the study.
Reagents. Nordihydroguaiaretic acid, NDGA 74540 Aldrich; (−)- Epigallocatechin gallate, EGCG E4143 
Sigma or 4524 Tocris; Terameprocol/mNDGA, T3455 Sigma; Catalase, C9322 Sigma; NDGA analogs NDGA-1, 
SECO-1, NDGA-5, cNDGA, and cNDGA-5 were generated, purified, and validated by Krol et al. at the University 
of Saskatchewan as previously described63.
Statistical analysis. Statistical analysis was conducted using Prism 5 software (GraphPad). Unpaired stu-
dents t test was used for comparisons between two groups. Comparisons involving multiple groups, such as 
molecule and dose comparisons, used two-way ANOVA with Tukey’s post hoc test for multiple comparisons. In 
all cases p < 0.05 was considered statically significant.
Data Availability
All data generated or analyzed during this study are included in this published article (and its Supplementary 
Information files).
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